87673-88-9

Usage

Uses

Used in Pharmaceutical Industry:
4,5,6,7-tetrahydro-1-methyl-1H-Imidazo[4,5-c]pyridine is used as a chemical intermediate for the synthesis of various bioactive compounds. Its unique structure allows it to be a key component in the development of new pharmaceuticals, contributing to the creation of innovative treatments and therapies.
Used in Chemical Industry:
In the chemical industry, 4,5,6,7-tetrahydro-1-methyl-1H-Imidazo[4,5-c]pyridine is utilized as a building block for the synthesis of a variety of materials. Its heterocyclic nature and fused ring system make it a valuable component in the development of advanced chemical products with specific properties and applications.
Despite its potential, financial constraints currently limit the large-scale production and availability of 4,5,6,7-tetrahydro-1-methyl-1H-Imidazo[4,5-c]pyridine. Further research and development are essential to fully explore and understand its potential uses and properties, which could lead to significant advancements in both the pharmaceutical and chemical sectors.

Upstream product

• 74-83-9 methyl bromide 
• 1026689-58-6 benzyl 3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5-carboxylate 
• 6882-74-2 4,5,6,7-tetrahydro-3H-imidazo[4,5-c]pyridine 
• 50-00-0 formaldehyd 
• 36475-47-5 3-methylhistamine dihydrochloride 
• 1421503-52-7 6,7-dihydro-4H-imidazo[4,5-c]pyridine-1,5-dicarboxylic acid di-tert-butyl ester 
• 6882-74-2 4,5,6,7-tetrahydro-1H-imidazo<4,5-c>pyridine 
• 1202800-68-7 1,4,6,7-tetrahydro-imidazo[4,5-c]pyridine-5-carboxylic acid tert-butyl ester 
• 74-88-4 methyl iodide 

Relevant academic research and scientific papers

Method for synthesizing methyl 1-methyl-imidazolyl-2-formate derivative

The invention provides a method for synthesizing a methyl 1-methyl-imidazolyl-2-formate derivative, and particularly relates to the technical field of medicines. The method comprises the following steps: S1, taking 3-methylhistamine dihydrochloride shown in the formula (II) as an initial raw material, carrying out a cyclization reaction process on the raw material and formaldehyde, and carrying out aftertreatment to obtain a compound 1-methyl-4, 5, 6, 7-tetrahydro-1H-imidazo[4, 5-c]pyridine shown in the formula (III), S2, enabling the N-5 site of the compound shown in the formula (III) to react with di-tert-butyl dicarbonate to generate a compound tert-butyl 1-methyl-6, 7-dihydro-1H-imidazo[4, 5-C]pyridin-5-(4H)-carboxylate shown in the formula (IV), S3, making active hydrogen at the C-2 site of the compound (IV) react with butyl lithium to generate a lithium salt, and then making the lithium salt react with carbon dioxide to generate a compound tert-butyl 1-methyl-6, 7-dihydro-1H-imidazo[4, 5-C]pyridin-5-(4H)-carboxylate-2-carboxylic acid shown in the formula (V), and S4, carrying out a condensation reaction process on the compound shown in the formula (V) and methanol to obtain the target compound shown in the formula (I). The method has the advantages of cheap and accessible raw materials, high reaction yield and low production cost, and can easily implement industrialization.

PRMT5 INHIBITORS AND USES THEREOF

Described herein are compounds of Formula (A), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof:wherein Y1 is of formula (?) or formula (y):Ring Y is a 5- to 6-membered heteroaryl ring; and V4, V5, Rx, x, y, and n are as defined herein. Compounds of the present invention are useful for inhibiting PRMT5 activity. Methods of using the compounds for treating PRMT5-mediated disorders are also described.

Anti-ulcer and antisecretory activity of selected imidazopiperidines

New thioureas and ureas with an interesting anti-ulcer and antisecretory activity are presented. The chemical synthesis, determination of the structure, and structure-activity relationships of the compounds are discussed.